ABIONYX Pharma provides an update on its activity and cash position for the first half of 2022
• Continuation of the concentration of the Services activity on preclinical studies of Biotech in ophthalmology
• Ongoing determination of the strategic axes of clinical development in ophthalmology
• Cash of €4.0 million (excluding CIR) as of June 30, 2022
Toulouse, FRANCE, Lakeland, UNITED STATES, August 18, 2022, 5:45 p.m. – ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies, today publishes its cash position for the first half ended June 30, 2022 and reviews the highlights of the period.